Salvage chemotherapy in patients with extragonadal nonseminomatous germ cell tumors: The Indiana University experience

Scott B. Saxman, Craig R. Nichols, Lawrence Einhorn

Research output: Contribution to journalArticle

91 Citations (Scopus)

Abstract

Purpose: Patients with relapsed extragonadal germ cell tumors (EGCT) are usually treated in an identical fashion as patients with recurrent testicular cancer. However, little is known about the long-term outcome in these patients and whether they have comparable results to patients with a testicular primary tumor. The purpose of this study was to evaluate the effect of salvage chemotherapy on long-term survival in patients with EGCT. Materials and Methods: We conducted a retrospective review of 73 patients with relapsed extragonadal nonseminomatous germ cell tumors (GCTs) treated at Indiana University between 1976 and 1993. All patients received cisplatin- containing regimens as primary chemotherapy. Results: Only five of 73 patients (7%) were long-term disease-free survivors after salvage chemotherapy. The remaining 68 patients are either dead of disease or toxicity (n = 63), or alive with progressive disease (PD) (n = 5). Twenty- eight patients received high-dose chemotherapy with autologous bone marrow transplant (ABMT) at some point during their disease, and none of these patients are continuously disease-free. Conclusion: Although similar salvage chemotherapy strategies will cure approximately 30% of patients with recurrent testicular cancer, new approaches are needed for EGCT.

Original languageEnglish
Pages (from-to)1390-1393
Number of pages4
JournalJournal of Clinical Oncology
Volume12
Issue number7
StatePublished - Jul 1994

Fingerprint

Drug Therapy
Germ Cell and Embryonal Neoplasms
Testicular Neoplasms
Nonseminomatous germ cell tumor
Cisplatin
Survivors
Bone Marrow
Transplants
Survival

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Salvage chemotherapy in patients with extragonadal nonseminomatous germ cell tumors : The Indiana University experience. / Saxman, Scott B.; Nichols, Craig R.; Einhorn, Lawrence.

In: Journal of Clinical Oncology, Vol. 12, No. 7, 07.1994, p. 1390-1393.

Research output: Contribution to journalArticle

@article{cd46f1eb5a9c4c5a98cbe429d3bc4da1,
title = "Salvage chemotherapy in patients with extragonadal nonseminomatous germ cell tumors: The Indiana University experience",
abstract = "Purpose: Patients with relapsed extragonadal germ cell tumors (EGCT) are usually treated in an identical fashion as patients with recurrent testicular cancer. However, little is known about the long-term outcome in these patients and whether they have comparable results to patients with a testicular primary tumor. The purpose of this study was to evaluate the effect of salvage chemotherapy on long-term survival in patients with EGCT. Materials and Methods: We conducted a retrospective review of 73 patients with relapsed extragonadal nonseminomatous germ cell tumors (GCTs) treated at Indiana University between 1976 and 1993. All patients received cisplatin- containing regimens as primary chemotherapy. Results: Only five of 73 patients (7{\%}) were long-term disease-free survivors after salvage chemotherapy. The remaining 68 patients are either dead of disease or toxicity (n = 63), or alive with progressive disease (PD) (n = 5). Twenty- eight patients received high-dose chemotherapy with autologous bone marrow transplant (ABMT) at some point during their disease, and none of these patients are continuously disease-free. Conclusion: Although similar salvage chemotherapy strategies will cure approximately 30{\%} of patients with recurrent testicular cancer, new approaches are needed for EGCT.",
author = "Saxman, {Scott B.} and Nichols, {Craig R.} and Lawrence Einhorn",
year = "1994",
month = "7",
language = "English",
volume = "12",
pages = "1390--1393",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "7",

}

TY - JOUR

T1 - Salvage chemotherapy in patients with extragonadal nonseminomatous germ cell tumors

T2 - The Indiana University experience

AU - Saxman, Scott B.

AU - Nichols, Craig R.

AU - Einhorn, Lawrence

PY - 1994/7

Y1 - 1994/7

N2 - Purpose: Patients with relapsed extragonadal germ cell tumors (EGCT) are usually treated in an identical fashion as patients with recurrent testicular cancer. However, little is known about the long-term outcome in these patients and whether they have comparable results to patients with a testicular primary tumor. The purpose of this study was to evaluate the effect of salvage chemotherapy on long-term survival in patients with EGCT. Materials and Methods: We conducted a retrospective review of 73 patients with relapsed extragonadal nonseminomatous germ cell tumors (GCTs) treated at Indiana University between 1976 and 1993. All patients received cisplatin- containing regimens as primary chemotherapy. Results: Only five of 73 patients (7%) were long-term disease-free survivors after salvage chemotherapy. The remaining 68 patients are either dead of disease or toxicity (n = 63), or alive with progressive disease (PD) (n = 5). Twenty- eight patients received high-dose chemotherapy with autologous bone marrow transplant (ABMT) at some point during their disease, and none of these patients are continuously disease-free. Conclusion: Although similar salvage chemotherapy strategies will cure approximately 30% of patients with recurrent testicular cancer, new approaches are needed for EGCT.

AB - Purpose: Patients with relapsed extragonadal germ cell tumors (EGCT) are usually treated in an identical fashion as patients with recurrent testicular cancer. However, little is known about the long-term outcome in these patients and whether they have comparable results to patients with a testicular primary tumor. The purpose of this study was to evaluate the effect of salvage chemotherapy on long-term survival in patients with EGCT. Materials and Methods: We conducted a retrospective review of 73 patients with relapsed extragonadal nonseminomatous germ cell tumors (GCTs) treated at Indiana University between 1976 and 1993. All patients received cisplatin- containing regimens as primary chemotherapy. Results: Only five of 73 patients (7%) were long-term disease-free survivors after salvage chemotherapy. The remaining 68 patients are either dead of disease or toxicity (n = 63), or alive with progressive disease (PD) (n = 5). Twenty- eight patients received high-dose chemotherapy with autologous bone marrow transplant (ABMT) at some point during their disease, and none of these patients are continuously disease-free. Conclusion: Although similar salvage chemotherapy strategies will cure approximately 30% of patients with recurrent testicular cancer, new approaches are needed for EGCT.

UR - http://www.scopus.com/inward/record.url?scp=0028200671&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028200671&partnerID=8YFLogxK

M3 - Article

C2 - 8021729

AN - SCOPUS:0028200671

VL - 12

SP - 1390

EP - 1393

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 7

ER -